Mirati Therapeutics announced a non-exclusive deal with Verastem Oncology (VSTM - Free Report) to conduct a clinical study on a combination of adagrasib, Mirati’s leading KRAS inhibitor candidate, and VS-6766, Verastem’s RAF/MEK inhibitor in KRAS G12C mutant non-small cell lung cancer (NSCLC).
The phase I/II study will determine the maximum tolerated dose and recommend the dose for a phase II study and also study the safety, tolerability and efficacy of the combination in patients who have progressed on a KRAS G12C inhibitor. Mirati and Verastem will jointly oversee the study.
In the year so far, the stock price of Mirati has declined 35.8% compared with the industry’s decline of 15.8%.
Mirati has initiated the submission of a new drug application (NDA) for adagrasib to treat patients with at least second-line NSCLC with KRAS G12C mutation, following prior systemic therapy. The company expects to complete the NDA submission by 2021-end.
The KRYSTAL-1 study is evaluating adagrasib in multiple cohorts in combination with other therapies. These include a combination of adagrasib with Merck’s (MRK - Free Report) Keytruda for first-line NSCLC, a combination of adagrasib plus Boehringer Ingelheim’s Gilotrif (afatinib) for advanced NSCLC and adagrasib combined with Lilly/Bristol-Myers’ (BMY - Free Report) Erbitux for second-line colorectal cancer (“CRC”).
Preliminary data from the adagrasib plus Merck’s Keytruda cohort demonstrated that the combination achieved 100% disease control rate with all seven patients exhibiting tumor regression ranging from 37% to 92% as of Oct 21, 2021.
In September 2021, the company reported top-line data from a cohort of the study, which demonstrated that both adagrasib monotherapy and adagrasib+ Lilly/Bristol-Myers’s Erbitux achieved significant clinical activity and broad disease control in patients with KRAS G12C mutated CRC.
A phase I/II combination study of adagrasib with Novartis' SHP2 inhibitor TNO-155 for advanced NSCLC and CRC is also currently ongoing.
Several pipeline data readouts are expected in 2022, which could be catalysts for the stock.
With regard to Verastem’s VS-6766, phase II studies are ongoing to evaluate VS-6766 in combination with defactinib in patients with recurrent low-grade serous ovarian cancer and patients with recurrent KRAS-G12V mutant NSCLC
Mirati currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Free Report – The Bitcoin Profit Phenomenon
Zacks Investment Research has released a Special Report to help you pursue massive profits from the world’s first and largest decentralized form of money.
No guarantees for the future, but in the past three presidential election years, Bitcoin’s returns were as follows: 2012 +272.4%, 2016 +161.1%, and 2020 +302.8%.
Zacks predicts another significant surge. Click below for Bitcoin: A Tumultuous Yet Resilient History.
Download Now – Today It’s FREE >>
Mirati Therapeutics announced a non-exclusive deal with Verastem Oncology (VSTM - Free Report) to conduct a clinical study on a combination of adagrasib, Mirati’s leading KRAS inhibitor candidate, and VS-6766, Verastem’s RAF/MEK inhibitor in KRAS G12C mutant non-small cell lung cancer (NSCLC).
The phase I/II study will determine the maximum tolerated dose and recommend the dose for a phase II study and also study the safety, tolerability and efficacy of the combination in patients who have progressed on a KRAS G12C inhibitor. Mirati and Verastem will jointly oversee the study.
In the year so far, the stock price of Mirati has declined 35.8% compared with the industry’s decline of 15.8%.
Mirati has initiated the submission of a new drug application (NDA) for adagrasib to treat patients with at least second-line NSCLC with KRAS G12C mutation, following prior systemic therapy. The company expects to complete the NDA submission by 2021-end.
The KRYSTAL-1 study is evaluating adagrasib in multiple cohorts in combination with other therapies. These include a combination of adagrasib with Merck’s (MRK - Free Report) Keytruda for first-line NSCLC, a combination of adagrasib plus Boehringer Ingelheim’s Gilotrif (afatinib) for advanced NSCLC and adagrasib combined with Lilly/Bristol-Myers’ (BMY - Free Report) Erbitux for second-line colorectal cancer (“CRC”).
Preliminary data from the adagrasib plus Merck’s Keytruda cohort demonstrated that the combination achieved 100% disease control rate with all seven patients exhibiting tumor regression ranging from 37% to 92% as of Oct 21, 2021.
In September 2021, the company reported top-line data from a cohort of the study, which demonstrated that both adagrasib monotherapy and adagrasib+ Lilly/Bristol-Myers’s Erbitux achieved significant clinical activity and broad disease control in patients with KRAS G12C mutated CRC.
A phase I/II combination study of adagrasib with Novartis' SHP2 inhibitor TNO-155 for advanced NSCLC and CRC is also currently ongoing.
Several pipeline data readouts are expected in 2022, which could be catalysts for the stock.
With regard to Verastem’s VS-6766, phase II studies are ongoing to evaluate VS-6766 in combination with defactinib in patients with recurrent low-grade serous ovarian cancer and patients with recurrent KRAS-G12V mutant NSCLC
Mirati currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Free Report – The Bitcoin Profit Phenomenon
Zacks Investment Research has released a Special Report to help you pursue massive profits from the world’s first and largest decentralized form of money.
No guarantees for the future, but in the past three presidential election years, Bitcoin’s returns were as follows: 2012 +272.4%, 2016 +161.1%, and 2020 +302.8%.
Zacks predicts another significant surge. Click below for Bitcoin: A Tumultuous Yet Resilient History.
Download Now – Today It’s FREE >>
Get the latest research report on BMY - FREE
Get the latest research report on MRK - FREE
Get the latest research report on VSTM - FREE